pharmaceutical daily

Immupharma adds COO to the board of directors

ImmuPharma,  the specialist drug discovery and development company, has appointed Dr Tim Franklin, Chief Operating Officer, to the Board of Directors.

Tim has worked with ImmuPharma for over three years, initially as a consultant and more recently was appointed as Chief Operating Officer in November 2020.  Tim’s key responsibilities include working closely with ImmuPharma’s clinical team and scientific advisors, as the Company looks to further progress its wider drug development portfolio, both through clinical development and partnering opportunities.

In addition, Tim will lead the relationship with Avion Pharmaceuticals, as the Company advances Lupuzor through its Phase 3 trial and regulatory processes involved in the ultimate approval of the drug.

Tim has over 30 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Commenting on the appointment, Tim McCarthy, Chairman said: “It is a pleasure to welcome Tim onto the Board of Directors. Tim has made an invaluable contribution to ImmuPharma over the last three years. During this time, he played a key role in negotiations, which resulted in the successful conclusion of the licensing deal with Avion Pharmaceuticals, our partner for Lupuzor, which is now close to embarking on its international Phase 3 trial. His extensive pharmaceutical and capital markets experience will contribute enormously to the team as we look to move into the next phase of our journey for the Company.”

Exit mobile version